New Sepracor drug gets FDA approval
By HME News Staff
Updated Tue October 31, 2006
MARLBOROUGH, Mass. - The Food and Drug Administration approved Sepracor's new nebulizer medication, Brovana, in October. The drug is the first long-acting beta2-agonist approved for use in an inhaler. Developed as a twice-daily treatment, the drug is expected to improve compliance rates in respiratory patients. Sepracor plans to launch Brovana during the second quarter of 2007.
Comments